Lynparza (olaparib) — CareFirst (Caremark)

Initial criteria

• Maintenance treatment of deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma as a single agent, in members whose disease has not progressed on ≥ 16 weeks of first-line platinum-based chemotherapy

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression

Approval duration

12 months